TORONTO, Oct. 21 /CNW/ - Canada's generic pharmaceutical industry will appear before the Senate Banking, Trade and Commerce Committee on October 22nd to discuss problems with Canada's Access to Medicines Regime (CAMR), which aims to deliver Canadian-made generic pharmaceuticals to developing countries facing health emergencies. The Committee is reviewing Bill S-232, which would correct many of the fundamental flaws with the regime and greatly streamline the CAMR process. Generic drug maker Apotex, the first and only company to attempt to use the regime, will discuss its experience in developing and shipping a triple-combination HIV/AIDS drug to Rwanda.
Date: Thursday, October 22, 2009
Time: 11:30 a.m. to 12:30 p.m.
Location: Room 9, Victoria Building 140 Wellington Street
Webcast: http://senparlvu.parl.gc.ca/ (BANK Meeting No. 29)
Witnesses: Jim Keon, President, Canadian Generic Pharmaceutical
Jack Kay, President and COO, Apotex Inc.
Bruce Clark, Vice President, Regulatory and Medical Affairs,
SOURCE Canadian Generic Pharmaceutical Association
For further information: For further information: Jeff Connell, Director of Public Affairs, Canadian Generic Pharmaceutical Association (CGPA), Tel: (416) 223-2333, Cell: (647) 274-3379, Email: firstname.lastname@example.org, Website: www.canadiangenerics.ca